WO1992008452A1 - Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales - Google Patents

Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales Download PDF

Info

Publication number
WO1992008452A1
WO1992008452A1 PCT/EP1991/002107 EP9102107W WO9208452A1 WO 1992008452 A1 WO1992008452 A1 WO 1992008452A1 EP 9102107 W EP9102107 W EP 9102107W WO 9208452 A1 WO9208452 A1 WO 9208452A1
Authority
WO
WIPO (PCT)
Prior art keywords
nabumetone
medicament
treatment
pharmaceutical composition
administration
Prior art date
Application number
PCT/EP1991/002107
Other languages
English (en)
Inventor
Giacomo Vaiani
Original Assignee
Dr. Lo. Zambeletti S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Lo. Zambeletti S.P.A. filed Critical Dr. Lo. Zambeletti S.P.A.
Publication of WO1992008452A1 publication Critical patent/WO1992008452A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Definitions

  • the present invention relates to a method for the treatment of myofascial pain syndromes and to a compound for use in such method.
  • U.S. Patent 4420639 describes 4-(6'-methoxy-2'- naphthyl)butan-2-one (nabumetone) and its use in the treatment of rheumatic and arthritic conditions.
  • MPS myofascial pain syndromes
  • the present invention provides a method for treating MPS in human or non-human animals, which comprises administering an effective, non-toxic amount of nabumetone to human or non-human animals suffering from MPS.
  • the present invention also provides the use of nabumetone in the manufacture of a medicament for use in the treatment of MPS.
  • a nabumetone medicament, for use in the treatment of MPS may be prepared by admixture of nabumetone with an appropriate carrier, which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • an appropriate carrier which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • the medicament is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of MPS.
  • the suitable dosage range for nabumetone depends on the , severity of the MPS and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • Nabumetone may be formulated for administration by any route, and examples are oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of nabumetone.
  • the medicaments may, for example, be in the form of tablets, dispersible tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • the medicaments may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinylpyrrolidon
  • Solid medicaments may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute nabumetone throughout those medicaments employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the medicament may also be.in the form of an ingestible capsule, for example of gelatin containing nabumetone if desired with a carrier or other excipients.
  • Medicaments for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid medicaments may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring
  • Nabumetone may also be administered by a non-oral route.
  • the medicaments may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil .or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a.solid form or concentrate which can be used to prepare an injectable formulation.
  • a unit dose will generally contain from 20 to 2000 mg and preferably will contain from 30 to 1000 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 750, 800 or 1000 mg.
  • the composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg.
  • the unit dose will contain from 2 to 20 mg of nabumetone and be administered in multiples, if desired, to give the preceding daily dose.
  • nabumetone compositions are in the form of 500 mg or 1000 mg swallow tablets.
  • the present invention further provides a pharmaceutical composition for use in the treatment of MPS which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for use in the treatment of MPS which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier.
  • Such compositions may be prepared in the manner as hereinbefore described.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Utilisation de nabumétone dans la fabrication d'un médicament destiné au traitement de syndromes de douleurs myofasciales.
PCT/EP1991/002107 1990-11-14 1991-11-06 Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales WO1992008452A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9024798.2 1990-11-14
GB909024798A GB9024798D0 (en) 1990-11-14 1990-11-14 Naphthyl derivative for treatment method

Publications (1)

Publication Number Publication Date
WO1992008452A1 true WO1992008452A1 (fr) 1992-05-29

Family

ID=10685389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/002107 WO1992008452A1 (fr) 1990-11-14 1991-11-06 Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales

Country Status (3)

Country Link
AU (1) AU8859191A (fr)
GB (1) GB9024798D0 (fr)
WO (1) WO1992008452A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061779A (en) * 1973-09-11 1977-12-06 Beecham Group Limited Naphthalene derivatives having anti-inflammatory activity
EP0167062A2 (fr) * 1984-06-29 1986-01-08 Beecham Group Plc Compositiontopique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061779A (en) * 1973-09-11 1977-12-06 Beecham Group Limited Naphthalene derivatives having anti-inflammatory activity
EP0167062A2 (fr) * 1984-06-29 1986-01-08 Beecham Group Plc Compositiontopique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Drugs, vol. 40, Supplement 5, 1990, Adis Int. Ltd, I. Stroehmann et al.: "German drug monitoring studies with nabumetone", pages 3842, see the whole article *
E.F. Reynolds: "Martindale The Extra Pharmacopoeia", 29th edition, 1989, The Pharmaceutical Press, (London, GB) see page 28 "Nabumetone" *
The Merck Index, 11th Ed., 1989, Merck & Co. Inc., Rahway, NJ (US), page 1002, see no. 6258 "Nabumetone" *
The Merck Manual, 15th ed., 1987, Merck & Co. Inc. Rahway, NJ (US), pages 1271-1272, see "Fibromyalgia" *

Also Published As

Publication number Publication date
GB9024798D0 (en) 1991-01-02
AU8859191A (en) 1992-06-11

Similar Documents

Publication Publication Date Title
US5371092A (en) Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
US4804669A (en) Treatment of pain with a piperidine
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
US6121291A (en) Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
US5695774A (en) Use of nabumetone or 6-methoxynaphthyl acetic acid for the treatment of dementia
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
US20020103250A1 (en) Method of treatment or prophylaxis
WO1992008452A1 (fr) Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales
WO1992008451A1 (fr) Utilisation de nabumetone pour le traitement de douleurs associees au cancer
WO1992004892A1 (fr) Utilisation de la nabumetone contre l'appauvrissement en calcium
WO1999053919A1 (fr) Traitement de trouble anxieux generalise avec de la paroxetine
MXPA00010343A (en) Treatment of generalized anxiety disorder with paroxetine
MXPA00000522A (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA